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OBJECTIVE—High cholesterol levels in circulating immune
complexes (IC), surrogate markers of modiﬁed LDL, are associ-
ated with increased carotid intima-media thickness (IMT) and
cardiovascular events in type 1 diabetes. Different modiﬁcations
of LDL are involved in IC formation, but which of these are
predictive of vascular events is not known. Therefore, we mea-
sured oxidized LDL (oxLDL), advanced glycation end products–
modiﬁed LDL (AGE-LDL), and malondialdehyde-modiﬁed LDL
(MDA-LDL) in IC and determined their relationship with in-
creased carotid IMT and compared the strength of the association
with that observed with conventional risk factors.
RESEARCH DESIGN AND METHODS—Levels of oxLDL,
AGE-LDL, and MDA-LDL were measured in circulating IC
isolated from sera of 479 patients of the Diabetes Control and
Complications Trial/Epidemiology of Diabetes Interventions and
Complications (DCCT/EDIC) cohort, collected at baseline. In-
ternal and common carotid IMT were measured 8 and 14 years
later by DCCT/EDIC.
RESULTS—OxLDL, AGE-LDL, and MDA-LDL levels in circulating
IC were signiﬁcantly correlated with diabetes duration, BMI, and
lipid and blood pressure, but not with age. Multivariate logistic
regression models indicated that individuals in the highest versus
lowest quartile of oxLDL and AGE-LDL in IC had a 6.11-fold
[conﬁdence interval (CI) 2.51–14.8] and a 6.4-fold (CI 2.53–16.2)
increase in the odds of having high carotid IMT, respectively, after
adjusting for conventional risk factors. Parallel analyses resulted in
odds ratios of 2.62 (CI 1.24, 5.55) for LDL-C, 1.45 (CI 0.69, 3.03) for
diastolic blood pressure, and 2.33 (CI 1.09, 4.99) for A1C.
CONCLUSIONS—OxLDL and AGE-LDL in circulating IC were
signiﬁcantly associated with progression and increased levels of
carotid IMT in type 1 diabetes. Diabetes 60:582–589, 2011
C
hronic inﬂammation has an established role in
the pathogenesis of atherosclerosis and acute
vascular events (1–3). Therefore, identiﬁcation
of factors that may trigger inﬂammation and
acute vascular events remains a high priority. Modiﬁed
forms of LDL have emerged as major factors in the path-
ogenesis of atherosclerosis, and oxidized LDL (oxLDL) has
been shown to trigger proinﬂammatory events (4–8) through
the activation of pathways associated with innate immunity
(4,6,9,10).
However, oxLDL is also involved in triggering adaptive
immunity pathways involved in the pathogenesis of ath-
erosclerosis (11,12). T cell activation appears to be linked
to LDL modiﬁcation since peptides derived from oxLDL
have been shown to be recognized by T cells (13). How-
ever, the strongest link between modiﬁed LDL and adap-
tive immunity involves the activation of the humoral
immune system. Most forms of modiﬁed LDL are immu-
nogenic and induce the formation of autoantibodies in
humans (14,15). A direct consequence of autoantibody
synthesis against modiﬁed LDL is the formation of immune
complexes (IC). These IC are detectable both in serum
(11) and in the atheromatous plaque, where both oxLDL
and oxLDL antibodies have been found (16,17).
The antibodies present in circulating IC isolated from
subjects with type 1 diabetes are predominantly IgG of the
proinﬂammatory subclasses 1 and 3 (18,19) and react with
oxLDL, malondialdehyde-modiﬁed LDL (MDA-LDL), and
advanced glycation end products–modiﬁed LDL (AGE-LDL)
(15). In vitro studies have demonstrated that oxLDL-IC have
proatherogenic and proinﬂammatory properties that greatly
exceed those of oxLDL (20).
In patients with type 1 diabetes, more than 90% of mod-
iﬁed LDL circulate as soluble IC and only traces of modiﬁed
lipoproteins circulating free are captured in the serum after
removal of IC (21). Therefore, to assess the relationship of
modiﬁed LDL with atherosclerosis, the modiﬁed lipoprotein
in IC needs to be measured, because the formation of sol-
uble IC interferes with the accuracy of the assays, both of
modiﬁed LDL antibodies and of modiﬁed LDL (14,21). In
contrast, the measurement of modiﬁed LDL levels obtained
from isolated IC appears to yield reproducible results, and
in the case of MDA-LDL, we showed that the capture assay
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ORIGINAL ARTICLEand a biochemical assay for MDA had an excellent corre-
lation (r =0 . 7 0 6 )( 2 1 ) .
In a small prospective study of 98 subjects with type 1
diabetes we have previously examined the role of modiﬁed
LDL-IC in the development of cardiovascular disease
(CVD) using the concentrations of cholesterol in IC
(22,23), as a surrogate marker for antibody-associated
modiﬁed LDL. The concentrations of cholesterol in the IC
correlated with the development of coronary artery dis-
ease over a period of 7 years (24,25). By use of the same
approach, we measured cholesterol in IC from a cohort of
1,050 individuals from the Diabetes Control and Compli-
cations Trial/Epidemiology of Diabetes Interventions and
Complications (DCCT/EDIC) study. We found that cho-
lesterol was present in signiﬁcantly higher concentrations
in the IC from patients who showed progression of the
internal carotid intima-media thickness (IMT) and that the
cholesterol content of IC was a signiﬁcant positive pre-
dictor of internal carotid IMT progression (26).
Subsequently, in our laboratory, we developed capture
immunoassays that allow us to quantify speciﬁcm o d i ﬁed
forms of LDL once they are dissociated from their corre-
sponding antibodies (21). We used these capture immuno-
assays to measure oxLDL, AGE- LDL, and MDA-LDL in
isolated and fractionated modiﬁed LDL-IC obtained from
stored serum samples collected from the DCCT/EDIC co-
hort at baseline and examined the relationship between the
concentration of oxLDL, AGE-LDL, and MDA-LDL in LDL-
IC and the carotid IMT measurements performed in the
DCCT/EDIC cohort ;8 and 14 years after the samples were
collected. This allowed us to address the hypothesis that the
levels of speciﬁcm o d i ﬁed forms of LDL in circulating IC
play a role in the development of vascular disease in type 1
diabetes and to compare their predictive value with that of
conventional predictors of CVD in type 1 diabetes.
RESEARCH DESIGN AND METHODS
This study was performed on a subgroup of 479 subjects from DCCT/EDIC
cohort. The DCCT cohort included 1,441 patients who were 13–39 years of age
and had type 1 diabetes for 1–15 years at study entry (27). None of the patients
at entry into the study (1983–89) had hypertension or dyslipidemia and
therefore were not on lipid-lowering or antihypertensive therapy.
The DCCT cohort was randomly assigned to intensive or conventional di-
abetes therapy and followed for an average of 6.5 years. In 1994, after intensive
therapy had been demonstrated to have major beneﬁcial effects on micro-
vascular complications, the interventional phase of the study was stopped and
the observational phase was initiated (28). During the ongoing EDIC obser-
vational phase, the patients have been under the care of their personal
physicians and encouraged to practice intensive diabetes therapy.
Of the 1,441 DCCT participants, 90–95%werefollowed duringEDICand 905of
these individuals had blood collected longitudinally as part of a substudy. From
these 905 subjects, 518 patients were selected for a case-control study of LDL-IC
and albuminuria. Patients with at least two measurements of albumin excretion
rate (AER) above 60 mg/24 h were selected as cases, and 3 to 4 patients without
albuminuria per patient with albuminuria were selected as controls. From the
518 subjects with LDL-IC measured, 479 had IMT measured during EDIC (29).
Serum samples were obtained after an overnight fast at entry into the DCCT
study and assayed at the time or stored at 280°C. The DCCT and EDIC were
approved by the Institutional Review Board of all participating DCCT/EDIC
centers, and all participants provided written informed consent.
Assessment of carotid IMT. Carotid ultrasonography was ﬁrst performed 1
to 2 years after initiation of EDIC (5–13 years after DCCT baseline) and re-
peated 5 years later. The measurement of IMT in the DCCT/EDIC cohort has
been described in detail (30,31). In brief, a single longitudinal lateral view of
the distal 10 mm of the right and left common carotid arteries (CCA) and three
longitudinal views in different imaging planes of each internal carotid artery
(ICA) were obtained by certiﬁed technicians at the clinical centers, recorded
on S-VHS tapes and read in a central unit (Tufts Medical Center, Boston, MA)
by a single reader, masked to participant characteristics. The maximum IMT
(in mm) of the CCA was deﬁned as the mean of the maximal IMT for near and
far walls on both right and left sides. The maximum IMT of the ICA was de-
ﬁned in the same way, and the results of the three scans (i.e., anterior, lateral,
and posterior views of both sides) were averaged.
Measurement of AGE-LDL, oxLDL, and MDA-LDL in human circulating
IC. We measured oxLDL, MDA-LDL, and AGE-LDL by ﬁrst precipitating cir-
culating IC from serum and then fractionating these IC by protein G afﬁnity
chromatography, separating the predominant IgG antibody from modiﬁed LDL,
as described previously (19,26). The reactivity of modiﬁed LDL separated from
LDL-IC with antibodies speciﬁc for different LDL modiﬁcations (oxLDL, MDA-
LDL, and AGE-LDL) was then assayed with capture assays developed in our
laboratory (21). The characteristics of the antibodies used in the assay and the
speciﬁcity and reproducibility of the capture assays have been reported pre-
viously (15,21). Coefﬁcients of variation for 50 samples measured in two
separate assays were 5.2% for oxLDL, 0.5% for MDA-LDL, and 8.3% for AGE-
LDL. The development of standards for calibration of the oxLDL, MDA-LDL,
and AGE-LDL assays, as well as sensitivity, reproducibility, and recovery data
for the capture assays, has been reported elsewhere (21). The levels of the
different LDL modiﬁcations in human circulating IC were expressed in func-
tion of the amount of apolipoprotein B contained in the IC, and the ﬁnal values
were given as the concentration per milliliter of serum.
Other procedures. At baseline DCCT, each participant completed a stan-
dardized medical history, physical examination, electrocardiogram, and lab-
oratory testing including hemoglobin A1c (28,32), fasting lipid proﬁles, and 4-h
urine collections for measurement of AER and creatinine clearance. Cova-
riates for the current analyses were obtained from DCCT baseline history,
physical examination, and laboratory data (fasting lipids and renal function).
The methodologies to measure conventional CVD risk factors have been de-
scribed elsewhere (28,32). Retinopathy status at baseline was assessed with
stereo fundus photography (33).
Statistical analysis. Prospective analyses were carried out in which the levels
of oxLDL, AGE-LDL, and MDA-LDL in LDL-IC, measured at baseline DCCT,
functionedasabiomarkerforindividuallevelsofLDL,degreeofoxidativestress,
and immune response. Internal and common IMT levels 8–14 years later (EDIC
years 1 and 6) were the outcomes of interest. All modiﬁed LDL values were
standardized to milligrams of apolipoprotein B per liters of serum and are
expressed as milligrams per liters; in addition, modiﬁed LDL values were log
transformed because of their skewed, nonnormal distribution. Spearman cor-
relations were determined for modiﬁed LDL levels and baseline DCCT variables
of interest. Means and proportions adjusted for treatment group, retinopathy
status, age, and sex were determined for participant DCCT baseline charac-
teristics stratiﬁed by modiﬁed LDL quartile using linear and logistic regression
as appropriate. Linear regression was used to determine estimates of the
b-coefﬁcient and semipartial R
2 for the relationship between the level of each
type of modiﬁed LDL measured in LDL-IC and internal and common IMT (ICA
and CCA IMT) measurements at EDIC years 1 and 6 and to calculate least
square means for EDIC years 1 and 6 ICA/CCA IMT across quartiles of each
modiﬁed LDL. Trends in both internal and common IMT across quartiles of each
modiﬁe dL D Lw e r et e s t e du s i n gaF-statistic obtained from a generalized linear
model adjusted for treatment group, retinopathy cohort, age, sex, diabetes du-
ration, hemoglobin A1c, logarithm of AER, and ultrasonography equipment.
Logistic regression was used to model two outcomes: 1) the odds ratio
associated with being in the upper versus lower measurements of ICA IMT
(i.e., upper quintile versus lower four quartiles) at EDIC year 6 and 2) the odds
ratio associated with high progression of ICA IMT from EDIC year 1 to EDIC
year 6 (i.e., high progression being deﬁned as being in the upper quintile of ICA
IMT change). For logistic regression analysis each IC was categorized into
quartiles. The association between modiﬁed LDL quartiles and being in the
upper quintile of ICA IMT was assessed separately for modiﬁed LDL after
controlling for the covariates included in the linear regression models with the
addition of LDL and HDL cholesterol, systolic and diastolic blood pressure,
and current smoking status. Additionally, for each IC studied appropriate in-
teraction terms were used to determine whether covariates modiﬁed the re-
lationship between each type of modiﬁed LDL and having high ICA IMT at
EDIC year 6. Finally, the c-statistic or area under the receiver operating curve
(ROC AUC) was used to compare the discriminatory power of various mul-
tivariate models. Parallel analyses were completed for the outcome high
progression of ICA IMT from EDIC year 1 to 6. Reported P values are two-
sided with a type I error rate for signiﬁcance of a = 0.05. All analysis were
performed using the SAS v. 9.2 system (SAS Institute, Cary, NC).
RESULTS
At DCCT baseline, the mean age of the study population
was 27.1 6 7.0 years, the mean duration of diabetes was
6.0 6 4.2 years, and 247 (51.6%) of the 479 subjects studied
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treatment group. A comparison of DCCT baseline charac-
teristics of the 479 subjects with the remaining DCCT co-
hort showed that duration of diabetes was longer, they
were more likely to have retinopathy at baseline, and BMI
and AER were higher. Blood pressure, lipid, and hemo-
globin A1c as well as age, sex, drinking, and smoking
status were similar in those included and excluded in this
study’s subcohort.
At DCCT baseline, the levels of oxLDL, AGE-LDL, and
MDA-LDL in isolated LDL-IC were signiﬁcantly correlated
with diabetes duration, BMI, and lipid and blood pressure
levels, but not with age. Correlations with LDL cholesterol,
although statistically signiﬁcant, were of moderate mag-
nitude (r = 0.15 to 0.23, P , 0.0007 to P , 0.0001). The
levels of MDA-LDL, AGE-LDL, and oxLDL in LDL-IC were
all highly intercorrelated (r = 0.71 to 0.83, P , 0.0001).
The percentage of men increased with increasing quar-
tiles of oxLDL in LDL-IC (Table 1). After treatment group,
retinopathy status, age, and sex were adjusted, the dura-
tion of diabetes remained similar while BMI, hemoglobin
A1c, LDL cholesterol, and triglyceride levels increased
across quartiles of oxLDL in LDL-IC. HDL cholesterol
levels decreased across increasing quartiles of oxLDL in
LDL-IC. Systolic blood pressure, diastolic blood pressure,
AER, and creatinine clearance did not increase or de-
crease across increasing oxLDL quartiles. Finally, neither
current smoking status nor alcohol consumption appeared
to be associated with oxLDL quartiles.
After covariates were adjusted, the concentrations of
modiﬁed LDL in isolated IC were each signiﬁcantly asso-
ciated with EDIC year 1 and EDIC year 6 ICA IMT with
higher modiﬁed LDL levels predicting higher ICA IMT
(Table 2). For common carotid artery IMT, associations
were slightly weaker with log MDA-LDL failing to predict
higher CCA IMT at EDIC year 1 or EDIC year 6. Addi-
tionally, log oxLDL and log AGE–LDL IC were associated
with progression of ICA and CCA IMT from EDIC year 1 to
EDIC year 6. With focus on mean ICA IMT levels as the
outcome and stratiﬁcation by oxLDL quartiles, ICA IMT
levels increased across oxLDL quartiles at EDIC year 1
(Linear Trend Test; P , 0.001) and EDIC year 6 (Linear
Trend Test; P , 0.001) after adjusting for treatment group,
retinopathy cohort, age, sex, diabetes duration, hemoglo-
bin A1c, logarithm of AER, and ultrasonography equip-
ment (Fig. 1A). Similar ﬁndings were observed across
AGE-LDL quartiles (Fig. 1B), whereas slightly weaker but
still statistically signiﬁcant ﬁndings were observed across
MDA-LDL quartiles (Fig. 1C).
Multivariate logistic regression models were used to
further examine the ability of the concentrations of oxLDL
and AGE-LDL in isolated LDL-IC to predict ICA IMT (Table
3). The outcome, high ICA IMT, was deﬁned as being in the
upper quintile as compared with the lower four quintiles of
ICA IMT at EDIC year 6 (high IMT deﬁned as .0.845 mm).
Individuals in the highest quartile of oxLDL in isolated
LDL-IC had a sevenfold increased odds [7.72 (95% CI 3.27,
18.3)] of having high versus normal ICA IMT relative to
those in the lowest quartile of oxLDL, after controlling for
treatment group, retinopathy cohort, age, sex, diabetes
duration, hemoglobin A1c, logarithm of AER, and ultra-
sonography equipment. Additionally, adjusting for LDL
cholesterol, HDL cholesterol, diastolic blood pressure, and
smoking status attenuated the odds ratios somewhat to
6.11 (95% CI 2.51, 14.8). Parallel analyses for AGE-LDL
resulted in odds ratios of 7.82 (95% CI 3.17, 19.3) and 6.40
(95% CI 2.53, 16.2), respectively. Parallel analyses for
MDA-LDL, not shown in Table 3, resulted in odds ratios of
2.74 (95% CI 1.27, 5.92) and 2.39 (95% CI 1.06, 5.38), re-
spectively. None of the covariates examined were found to
modify associations between oxLDL or AGE-LDL levels in
isolated LDL-IC and having high ICA IMT at EDIC year 6.
Similar analyses were completed to examine the ability
of oxLDL and AGE-LDL in isolated LDL-IC to predict
progression of ICA IMT (Table 4). The outcome, high
progression of ICA IMT, was deﬁned as being in the upper
TABLE 1
DCCT baseline characteristics (means or proportions and 95% conﬁdence intervals) of the study population stratiﬁed by quartile of
oxLDL in LDL-IC (n = 479) adjusted for treatment group, retinopathy cohort, age, and sex
oxLDL in LDL-IC quartiles (cut points, mg/L) Trend
1st (5–89) 2nd (90–162) 3rd (163–305) 4th (306–1382) P
Age (years)* 27.0 (25.7, 28.2) 27.1 (25.9, 28.4) 27.3 (26.0, 28.5) 27.1 (25.9, 28.4) 0.8235
Men (%)* 42.0 (33.5, 51.0) 47.5 (38.7, 56.4) 59.2 (50.2, 67.6) 57.5 (48.5, 66.0) 0.0047
Intensive treatment group (%)* 52.1 (43.2, 60.9) 48.3 (39.5, 57.2) 46.7 (37.9, 55.6) 35.8 (27.8, 44.8) 0.0135
Primary retinopathy cohort (%)* 54.6 (45.6, 63.3) 44.2 (35.6, 53.1) 51.7 (42.8, 60.5) 70.8 (62.1, 78.3) 0.0058
Diabetes duration (years) 5.5 (5.0, 6.0) 6.5 (6.0, 7.0) 6.1 (5.6, 6.6) 5.9 (5.4, 6.4) 0.4827
Hemoglobin A1c (%) 8.7 (8.4, 9.0) 8.6 (8.3, 8.8) 8.9 (8.6, 9.2) 9.3 (9.0, 9.6) 0.0014
Body mass index (kg/m
2) 23.1 (22.6, 23.6) 23.3 (22.8, 23.8) 23.4 (22.9, 23.9) 24.1 (23.6, 24.6) 0.0062
Blood pressure (mmHg)
Systolic 113 (111, 115) 115 (113, 117) 115 (113, 117) 115 (113, 117) 0.2216
Diastolic 73 (71, 74) 73 (71, 74) 73 (71, 74) 74 (73, 76) 0.2266
Cholesterol (mg/dL)
HDL 53 (51, 55) 51 (49, 53) 50 (48, 52) 49 (47, 51) 0.0058
LDL 103 (98, 108) 102 (97, 108) 113 (108, 118) 118 (113, 123) ,0.0001
Triglycerides (mg/dL)† 66 (62, 71) 68 (63, 73) 76 (70, 81) 82 (77, 88) ,0.0001
AER (mg/24 h)† 10.7 (9.4, 12.3) 11.6 (10.2, 13.3) 12.5 (10.9, 14.3) 12.6 (11.0, 14.4) 0.0754
Creatinine clearance (ml/min) 125 (120, 129) 126 (121, 131) 131 (126, 136) 125 (121, 130) 0.4882
Current smoker (%) 13.5 (8.4, 20.9) 25.6 (18.4, 34.4) 17.0 (11.3, 24.8) 23.3 (16.3, 32.2) 0.2083
Current drinker (%) 26.9 (19.3, 36.0) 14.0 (8.8, 21.5) 16.7 (11.1, 24.5) 16.5 (10.8, 24.3) 0.0961
*Unadjusted. †Because of nonnormal distributions, geometric means are presented.
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change in ICA IMT from EDIC year 1 to 6 (high IMT change
deﬁned as ICA IMT year 6 2 year 1 . 0.179 mm). Adjusted
odds ratios for ICA IMT progression were 4.08 (95% CI
1.80–9.23) and 2.62 (95% CI 1.18–5.79), respectively, for
oxLDL and AGE-LDL in isolated LDL-IC comparing the
highest with the lowest LDL-IC quartile.
Finally, a comparison of the discriminatory power of
oxLDL and AGE-LDL concentrations in isolated LDL-IC
with that of LDL cholesterol, diastolic blood pressure,
AER, and hemoglobin A1c shows the adjusted odds ratios
for having high versus normal ICA IMT, comparing those
in the highest versus lowest quartile of LDL cholesterol,
diastolic blood pressure, AER, and hemoglobin A1c, were
2.62 (95% CI 1.24, 5.55), 1.45 (95% CI 0.69, 3.03), 1.61 (95%
CI 0.73, 3.56), and 2.33 (95% CI 1.09, 4.99), respectively
(Fig. 2). Furthermore, ROC AUC, used as mentioned in
methods to compare the discriminatory power of the var-
ious multivariate models, were 0.750, 0.740, and 0.739,
respectively, for LDL cholesterol, diastolic blood pressure,
and AER models, and 0.747 for the hemoglobin A1c model.
In comparison, the ROC AUC for the analogous models
for oxLDL and AGE-LDL in LDL-IC were 0.794 and 0.790,
respectively.
DISCUSSION
Our study has shown that high levels of oxLDL and AGE-LDL
in circulating IC, even when measured at a very young age
TABLE 2
Adjusted linear regression models for modiﬁe dL D Li nL D L - I C *
predicting internal and common carotid IMT
b-Coefﬁcient
estimate P
Semipartial
R
2 (%)
Internal IMT (mm)–EDIC
year 1
Ln oxLDL in IC† 0.05965 ,0.0001 4.28
Ln AGE-LDL in IC† 0.04684 ,0.0001 4.25
Ln MDA-LDL in IC† 0.02369 0.0306 1.03
Common IMT (mm)–EDIC
year 1
Ln oxLDL in IC† 0.00855 0.0460 0.85
Ln AGE-LDL in IC† 0.00645 0.0562 0.78
Ln MDA-LDL in IC† 0.00282 0.4181 0.14
Internal IMT (mm)–EDIC
year 6
Ln oxLDL in IC† 0.11000 ,0.0001 5.52
Ln AGE-LDL in IC† 0.08942 ,0.0001 5.89
Ln MDA-LDL in IC† 0.04208 0.0172 1.24
Common IMT (mm)–
EDIC year 6
Ln oxLDL in IC† 0.01908 0.0035 1.82
Ln AGE-LDL in IC† 0.01475 0.0043 1.76
Ln MDA-LDL in IC† 0.00781 0.1420 0.47
Internal IMT progression
(mm)–year 6 adjusted
for year 1
Ln oxLDL in IC‡ 0.05904 0.0015 2.24
Ln AGE-LDL in IC‡ 0.05036 0.0006 2.63
Ln MDA-LDL in IC‡ 0.02178 0.1437 0.48
Common IMT progression
(mm)–year 6 adjusted
for year 1
Ln oxLDL in IC‡ 0.01318 0.0225 1.12
Ln AGE-LDL in IC‡ 0.01014 0.0262 1.07
Ln MDA-LDL in IC‡ 0.00603 0.1976 0.36
*b-Coefﬁcient estimates are per unit increase in natural log trans-
formed levels of modiﬁed LDL forms in isolated LDL-IC (in mg/L).
†Adjusted for DCCT treatment group; DCCT retinopathy cohort; and
baseline DCCT age, sex, diabetes duration, hemoglobin A1c (%), log-
arithm of AER, and ultrasonography equipment. ‡Additionally, ad-
justed for EDIC year 1 IMT level; EDIC year 6 adjusted for EDIC
year 1 is equivalent to progression from year 1 to year 6 adjusted
for year 1.
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FIG. 1. Internal IMT means (in millimeters) for years 1 and 6 adjusted
for age, sex, study group, retinopathy status, duration of diabetes at
study entry, percent hemoglobin A1c, logarithm of AER, and ultraso-
nography equipment. A: The quartiles of oxLDL in isolated LDL-IC are
as follows: 1, 5–89 (mg/L); 2, 90–162; 3, 163–305; and 4, 306–1382.
Linear Trend Test: year 1 (F = 27.21; P < 0.001); year 6 (F = 27.91; P <
0.001). B: The quartiles of AGE in isolated LDL-IC are as follows: 1,
0.15–2.64 (mg/L); 2, 2.65–6.42; 3, 6.43–12.03; and 4, 12.17–305.34. Lin-
ear Trend Test: year 1 (F = 25.28; P < 0.001); year 6 (F = 24.85; P <
0.001). C: The quartiles of MDA in isolated LDL-IC are as follows: 1, 3–
43 (mg/L); 2, 44–108; 3, 109–202; and 4, 203–1296. Linear Trend Test:
year 1 (F = 4.59; P = 0.033); year 6 (F = 6.39; P = 0. 012).
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disease, are strongly predictive of increased IMT and thick-
ening over a period of 8–14 years. The associations of the
modiﬁed lipoprotein levels in circulating IC with ICA IMT
were generally larger than those of classical predictive fac-
tors such as albumin excretion rate, LDL cholesterol, he-
moglobin A1c, or blood pressure.
The intercorrelation between the levels of MDA-LDL,
AGE-LDL, and oxLDL in circulating IC was to be expected,
since the precipitated IC are not necessarily made of LDL
molecules with single modiﬁcations but rather of LDL mole-
cules with multiple epitopes formed by different mechanisms,
recognized by antibodies of different speciﬁcities. Further-
more, some of the epitopes, such as carboxymethyllysine
(CML), are shared by AGE-LDL and oxLDL (15). Therefore,
our measurements reﬂect the relative distribution of epitopes
related to copper oxidation, MDA, and AGE modiﬁcations in
the population of modiﬁed LDL molecules involved in IC
TABLE 4
Adjusted* odds ratios (and 95% conﬁdence intervals) from multivariate logistic regression models for a given difference in risk factor
level for being in the upper quintile versus the lower four quintiles† of progression of ICA IMT from EDIC year 1 to EDIC year 6
IC
oxLDL in LDL-IC
Model 1
AGE-LDL in LDL-IC
Model 2
Quartile
Lowest 1.00 1.00
2 1.33 (0.53–3.29) 1.66 (0.73–3.79)
3 2.29 (0.98–5.35) 1.65 (0.73–3.72)
4 4.08 (1.80–9.23) 2.62 (1.18–5.79)
Age (1-year increase) 1.05 (1.01–1.10) 1.05 (1.01–1.09)
Sex (men vs. women) 1.07 (0.60–1.93) 1.09 (0.61–1.94)
Study group (intensive vs. conventional) 0.88 (0.51–1.50) 0.84 (0.50–1.42)
Retinopathy cohort (second vs. primary) 0.55 (0.25–1.23) 0.60 (0.28–1.36)
Duration (1-year increase) 1.08 (0.99–1.18) 1.09 (0.99–1.19)
Hemoglobin A1c (1-unit increase, %) 1.05 (0.88–1.24) 1.08 (0.91–1.27)
Ln of AER (1-unit increase, mg/24 h) 0.98 (0.67–1.43) 0.95 (0.65–1.37)
Cholesterol (10 unit increase, mg/dL)
LDL 1.06 (0.97–1.16) 1.07 (0.98–1.17)
HDL 0.80 (0.62–1.04) 0.77 (0.60–0.99)
Diastolic blood pressure‡ (10-unit increase, mmHg) 1.47 (1.05–2.06) 1.55 (1.11–2.17)
Current smoking (yes vs. no) 2.25 (1.22–4.15) 2.25 (1.23–4.14)
Year 1 IMT 1.96 (0.78–4.88) 2.24 (0.89–5.64)
ROC AUC 0.779 0.764
*Both models are additionally adjusted for ultrasonography equipment. †The numerical cut point for high IMT progression from EDIC year 1
to EDIC year 6 was greater than 0.179 mm. ‡Diastolic rather than systolic blood pressure was included because although not signiﬁcantly
associated with high ICA IMT, it was a stronger predictor than systolic blood pressure in our study population.
TABLE 3
Adjusted* odds ratios (and 95% conﬁdence intervals) from multivariate logistic regression models for a given difference in risk factor
level for being in the upper quintile versus the lower four quintiles† of ICA IMT at EDIC year 6
IC
oxLDL in LDL-IC AGE-LDL in LDL-IC
Model 1 Model 2 Model 3 Model 4
Quartile
Lowest 1.00 1.00 1.00 1.00
2 1.98 (0.78, 5.02) 1.77 (0.68, 4.60) 3.65 (1.44, 9.26) 3.66 (1.40, 9.56)
3 3.27 (1.35, 7.91) 2.88 (1.16, 7.15) 2.71 (1.06, 6.93) 2.75 (1.05, 7.21)
4 7.72 (3.27, 18.3) 6.11 (2.51, 14.8) 7.82 (3.17, 19.3) 6.40 (2.53, 16.2)
Age (1-year increase) 1.12 (1.08, 1.17) 1.10 (1.06, 1.15) 1.12 (1.07, 1.16) 1.10 (1.05, 1.15)
Sex (men vs. women) 1.97 (1.16, 3.35) 1.27 (0.69, 2.33) 2.10 (1.24, 3.57) 1.30 (0.71, 2.38)
Study group (intensive vs. conventional) 0.72 (0.42, 1.22) 0.67 (0.39, 1.16) 0.68 (0.40, 1.15) 0.64 (0.37, 1.11)
Retinopathy cohort (second vs. primary) 0.58 (0.26, 1.28) 0.51 (0.22, 1.18) 0.69 (0.32, 1.48) 0.60 (0.27, 1.35)
Duration (1-year increase) 1.07 (0.98, 1.17) 1.08 (0.98, 1.18) 1.09 (0.99, 1.19) 1.09 (1.00, 1.20)
Hemoglobin A1c (1-unit increase, %) 1.08 (0.91, 1.28) 1.06 (0.89, 1.26) 1.11 (0.94, 1.31) 1.08 (0.91, 1.29)
Ln of AER (1-unit increase, mg/24 h) 1.14 (0.78, 1.66) 0.95 (0.64, 1.41) 1.11 (0.77, 1.62) 0.93 (0.62, 1.37)
Cholesterol (10-unit increase, mg/dL)
LDL —- 1.10 (1.00, 1.21) —- 1.11 (1.02, 1.22)
HDL —- 0.69 (0.53, 0.91) —- 0.67 (0.51, 0.88)
Diastolic blood pressure‡ (10-unit increase, mmHg) —- 1.39 (0.99, 1.95) —- 1.52 (1.07, 2.15)
Current smoking (yes vs. no) —- 2.31 (1.25, 4.26) —- 2.23 (1.19, 4.15)
ROC AUC 0.794 0.818 0.790 0.817
*All models are additionally adjusted for ultrasonography equipment. †The numerical cut point for high IMT at EDIC year 6 was greater than
0.845 mm. ‡Diastolic rather than systolic blood pressure was included because although not signiﬁcantly associated with high ICA IMT, it was
a stronger predictor than systolic blood pressure in our study population.
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predictive of ICA IMT. We have shown that copper-oxidized
LDL contains non-MDA epitopes recognized by human anti-
bodies (15). This observation suggests that although MDA
epitopes are present in modiﬁe dL D Lf r o mi s o l a t e dI C ,t h e
antibodies involved in IC formation react predominantly with
non-MDA epitopes, and this could explain why the mea-
surement of oxLDL in isolated LDL-IC is a better predictor of
elevated carotid artery IMT.
The proinﬂammatory properties of LDL-IC have been
well characterized (34). Their pathogenic potential results
from the fact that human modiﬁed LDL antibodies are
predominantly of the IgG isotype, which can diffuse easily
across the endothelial barrier. In addition, modiﬁed LDL
antibodies are predominantly of the IgG1 and IgG3 iso-
types (14,19,20,35,36), able to activate the complement
system by the classical pathway (37) and to interact with
Fcg-receptors in phagocytic cells (38), speciﬁcally mac-
rophages in the vessel wall, and therefore promote cell
activation and inﬂammation. Given that both circulating
and complexed human autoantibodies to both oxLDL and
AGE-LDL are predominantly IgG of the IgG1 an IgG3 iso-
types (14,19,20,35,36), it would be fully expected that they
could play a pathogenic role in chronic inﬂammatory
processes, such as atherosclerosis.
A limitation of our study is that the measurement of
modiﬁed lipoproteins in IC isolated from peripheral blood
is only a surrogate marker for the formation of extravascular
IC; however, it is very likely that these peripheral IC levels
are reasonable surrogate markers since both modiﬁed LDL
and the corresponding antibodies have been identiﬁed in
atheromatous lesions (16,17). A second limitation of the
study is that the 479 participants with IC measurements
available, because selected for a case-control study of al-
buminuria, were not a random sample of the entire DCCT/
EDIC study population. To overcome this selection bias
we have controlled for DCCT retinopathy cohort, AER,
diabetes duration, and hemoglobin A1c, and we deter-
mined that covariates, including DCCT treatment group,
were not acting as effect modiﬁers of associations of in-
terest, indicating that the predictive ability of modiﬁed
LDL-IC was similar across different levels of these variables.
However, there may still be some residual confounding,
which we were unable to account for in our analysis.
The measurement of LDL modiﬁcations in isolated IC
reﬂects three important steps in the development of the
arteriosclerotic process: increased levels of LDL cholesterol,
clearly associated with the development of atherosclerosis;
increased oxidation and glycoxidative modiﬁcation of LDL
in diabetes; and the impact of the humoral immune re-
sponse in the inﬂammatory process associated with ath-
erosclerosis.
Although AGE-LDL modiﬁcation is more accentuated
in hyperglycemic patients, LDL oxidation seems to be a
universal event, affecting the general population. The same
predominance of IgG1 and IgG3 oxLDL antibodies also has
0.13     0.25    0.50      1         2          4          8         16         32
Biomarker Quartile Odds Ratio (95% Confidence Interval)
ox-LDL-IC       2nd
3rd
4th
AGE-LDL-IC    2nd
3rd
4th
LDL                 2nd
3rd
4th
DBP                 2nd
3rd
4th
AER                 2nd
3rd
4th
HbA1C%         2nd
3rd
4th
FIG. 2. Adjusted* odds ratios with 95% conﬁdence intervals (calculated from multivariate logistic regression models) for given levels of oxLDL in
isolated LDL-IC, AGE-LDL in isolated LDL-IC, LDL cholesterol, diastolic blood pressure (DBP), albumin excretion rate (AER), and hemoglobin
A1c (levels in the 2nd, 3rd, and 4th quartiles relative to quartile 1) to predict internal carotid artery IMT at EDIC year 6. OxLDL-IC categories are
5–89, 90–162, 163–305, and 306–1382 mg/L; AGE-LDL-IC categories are 0.15–2.64, 2.65–6.42, 6.43–12.03, and 12.17–305.34 mg/L; LDL categories
are 29–89, 90–105, 106–126, and 127–219 mg/dL; DBP categories are 40–66, 68–73, 74–79, and 80–98 mmHg; AER categories are 1.4–6.0, 7.0–10, 11–
19, and 20–151 mg/24 h; hemoglobin A1c categories are 5.9–7.7, 7.7–8.5, 8.5–9.9, and 9.9–14.4%. High carotid artery IMT was deﬁned as being in the
upper quintile as compared with the lower 4 quintiles of internal carotid artery IMT at EDIC year 6. The numerical cut point for high IMT at EDIC
year 6 was greater than 0.845 mm. *Adjusted for age, sex, study group, retinopathy status, duration of diabetes at study entry, logarithm of AER
(except for when AER is the categorical variable), percent hemoglobin A1c (except for when hemoglobin A1c is the categorical variable), and
ultrasonography equipment.
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(18). Therefore, the pathogenic role of modiﬁed LDL in
circulating IC should not be limited to diabetic patients.
However, it is possible that patients with type 1 diabetes not
only generate higher levels of modiﬁed LDL through glyco-
oxidative processes but, given the complex constellation of
genetic factors associated with their autoimmune disease,
they could have an enhanced and more potent autoimmune
response to modiﬁed lipoproteins. It is therefore quite im-
portant to investigate whether the same high predictive
value of modiﬁed LDL in circulating IC for CVD events is
also present in type 2 diabetes and in the general population.
Regardless of the results of such studies, it is, however,
quite clear that high levels of oxLDL and AGE-LDL in cir-
culating IC have a major impact on the progression of
carotid IMT in type 1 diabetes and they may help to
identify patients at high risk for CVD events.
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